IDYA
NEUTRALProductIDEAYA Biosciences, Inc.
Price
$39.67
+1.43%This is the 2026-08-21 snapshot — the signals and analysis for IDYA as of this single trading day.
View full IDYA research hub →Score9.5Priority
Signals3/8 DNA2/13 Act · 0/4 Risk
SentimentNEUTRALScore: 8
Volume1.1xvs 20d avg
Analysis
IDYA is exhibiting a textbook High-Conviction Price Discovery phase, driven by the August 19 announcement of a clinical collaboration with Genentech for its PRMT5 inhibitor IDE892. This fundamental catalyst aligns perfectly with bullish technical signals—including a PERFECT_STACK and QUIET_ACCUMULATION—and a robust 12.1% monthly gain that easily outpaces the broader market. Furthermore, the prevailing RISK_ON macro regime, fueled by Treasury liquidity injections and tight credit spreads, creates an ideal structural environment for investors to bid up high-beta biotech assets with de-risked clinical pipelines.
Fired Signals
STEADY CLIMBGOLDEN CROSSPERFECT STACKQUIET ACCUMULATIONINSIDE OUT
Key Takeaways
- Actionable Thesis: IDYA is a high-conviction buy driven by the recent Genentech collaboration and positive OptimUM-02 trial results, which provide massive fundamental validation for its oncology pipeline.
- Key Risk: The stock remains vulnerable to a sudden macro liquidity contraction or unexpected regulatory setbacks, which could trigger a sharp mean reversion.
- What to Watch: Monitor the $35.40 support level to confirm the structural uptrend remains intact alongside progress on the upcoming darovasertib NDA filing.
© 2026 Signal52 • For educational purposes only